Pharmacoeconomic analyses: whose perspective counts and costs the most?
Rubenstein
E B
EB
Department of Medical Specialties, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Elting
L S
LS
D000328:Adult; D002945:Cisplatin / Q000009:adverse effects; D003362:Cost-Benefit Analysis / Q000379:methods*; D003663:Decision Trees; D004341:Drug Evaluation / Q000191:economics* / Q000639:trends; D006801:Humans; D008787:Metoclopramide / Q000191:economics / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D017294:Ondansetron / Q000191:economics / Q000627:therapeutic use; D011788:Quality of Life; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D017294:Ondansetron; D008787:Metoclopramide; D002945:Cisplatin